Affimed Therapeutics (AFMD) has released an update.
Affimed Therapeutics has reported significant clinical progress in 2023, with promising responses in their three main programs targeting different forms of cancer, and expects to deliver key clinical data in the second quarter of 2024. The company has successfully completed corporate restructuring, reducing its workforce by 50% to focus on advancing these clinical programs. With a cash reserve of €72.0 million as of the end of 2023, Affimed is well-funded to continue operations into the second half of 2025.
For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.
